Abstracts tagged "mononeuritis multiplex"

Abstract Number: 2784 • ACR/ARHP Annual Meeting 2013
Mononeuritis Multiplex Predicts The Need For Immunosuppressive Or Immunomodulatory Drugs For Eosinophilic Granulomatosis With Polyangiitis, Polyarteritis Nodosa and Microscopic Polyangiitis Patients Without Poor-Prognosis Factors
Maxime Samson¹, Xavier Puéchal², Hervé Devilliers³, Camillo Ribi⁴, Pascal Cohen⁵, Boris Bienvenu⁶, Christian Pagnoux⁷, Luc Mouthon², Loic Guillevin⁸ and French Vasculitis Study Group (FVSG)², ¹Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France; Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ²Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ³Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ⁴Immunology and Allergology, Internal Medicine, University Hospitals of Geneva, Geneva, Switzerland, Geneva, Switzerland, ⁵National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁶Division of Internal Medicine, Centre Hospitalier Régional Universitaire de Caen, Côte de Nacre, Caen, France, Caen, France, ⁷Rheumatology, Mount Sinai Hospital, Toronto, Canada, Toronto, ON, Canada, ⁸Department of Internal Medicine,, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France
Background/Purpose: Patients with eosinophilic granulomatosis with polyangiitis (EGPA), polyarteritis nodosa (PAN) or microscopic polyangiitis (MPA) without poor-prognosis factors, as defined by their 1996 Five-Factor Scores…